Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.40 +1.7%	$4.66	$1.00 ▼ $7.00	$47.88M	0.67	177,767 shs	36,738 shs
CRDF Cardiff Oncology	$2.39 -0.8%	$3.52	$2.09 ▼ $5.64	$159M	1.54	3.21 million shs	1.23 million shs
DMAC DiaMedica Therapeutics	$4.67 -3.1%	$4.09	$3.19 ▼ $6.82	$241.39M	1.25	451,717 shs	390,287 shs
RAPT Rapt Therapeutics	$9.81 -4.3%	$9.45	$5.67 ▼ $26.56	$162.24M	0.01	94,594 shs	25,131 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	+7.78%	+37.40%	+12.50%	+315.38%
CRDF Cardiff Oncology	0.00%	-9.47%	-42.55%	-10.15%	+11.68%
DMAC DiaMedica Therapeutics	0.00%	+13.35%	+27.25%	+24.20%	+43.69%
RAPT Rapt Therapeutics	0.00%	-6.48%	+13.81%	+59.25%	-49.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	1.7119 of 5 stars	3.3	3.0	0.0	1.1	1.7	0.0
CRDF Cardiff Oncology	1.6812 of 5 stars	3.4	0.0	0.0	2.3	1.7	0.6
DMAC DiaMedica Therapeutics	1.8752 of 5 stars	3.5	1.0	0.0	3.0	1.7	0.0
RAPT Rapt Therapeutics	4.2866 of 5 stars	4.3	1.0	4.2	1.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	122.22% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	322.59% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$10.75	130.19% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.43	118.44% Upside

Current Analyst Ratings Breakdown

Latest ATHE, DMAC, CRDF, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
CRDF Cardiff Oncology	$680K	233.83	N/A	N/A	$1.86 per share	1.28
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
RAPT Rapt Therapeutics	$1.53M	106.05	N/A	N/A	$11.51 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	8/14/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/12/2025 (Confirmed)
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-69.03%	-59.56%	N/A

Latest ATHE, DMAC, CRDF, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
CRDF Cardiff Oncology	N/A	4.42	4.42
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
CRDF Cardiff Oncology	16.29%
DMAC DiaMedica Therapeutics	10.12%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
CRDF Cardiff Oncology	7.70%
DMAC DiaMedica Therapeutics	7.30%
RAPT Rapt Therapeutics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	15.45 million	Optionable

ATHE, DMAC, CRDF, and RAPT Headlines

Recent News About These Companies

Rapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street Zen

August 10 at 3:33 AM | marketbeat.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7 at 8:00 AM | globenewswire.com

Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

August 7 at 2:34 AM | marketbeat.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded to Neutral at JPMorgan Chase & Co.

August 1, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31, 2025 | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board

July 15, 2025 | tmcnet.com

Best Momentum Stocks to Buy for July 15th

July 15, 2025 | zacks.com

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

July 15, 2025 | zacks.com

New Strong Buy Stocks for July 15th

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?
By Sam Quirke | July 29, 2025
View Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?
Realty Income Rallies Post-Earnings Miss—Here’s What Drove It
By Gabriel Osorio-Mazilli | August 7, 2025
View Realty Income Rallies Post-Earnings Miss—Here’s What Drove It

ATHE, DMAC, CRDF, and RAPT Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.40 +0.09 (+1.69%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$5.38 -0.02 (-0.37%)

As of 08/8/2025 07:59 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Cardiff Oncology NASDAQ:CRDF

$2.39 -0.02 (-0.83%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/8/2025 07:53 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DiaMedica Therapeutics NASDAQ:DMAC

$4.67 -0.15 (-3.11%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.67 0.00 (0.00%)

As of 08/8/2025 04:10 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Rapt Therapeutics NASDAQ:RAPT

$9.81 -0.44 (-4.29%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.82 +0.00 (+0.05%)

As of 08/8/2025 04:12 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time